BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

NCT01214616 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: afatinib 20mg
DRUG: afatinib 40mg
DRUG: vinorelbine IV 25 or 20mg/m2

Sponsor

Boehringer Ingelheim